Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients

Date

09 Oct 2016

Session

Poster display

Presenters

Matti Aapro

Citation

Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390

Authors

M.S. Aapro1, S. Arora2, D. Powers3

Author affiliations

  • 1 Oncology, IMO Clinique de Genolier, 1272 - Genolier/CH
  • 2 Biostatistics, TESARO, Inc., Waltham/US
  • 3 Medical Affairs, TESARO, Inc., Waltham/US
More

Resources

Abstract 3838

Background

Although older patients (pts) may have less CINV compared with younger ones, preventative treatments with a good safety profile are needed. This analysis evaluates the efficacy and safety of the long-acting neurokinin-1 receptor antagonist (RA) rolapitant according to pt age (

Methods

In 3 double-blind studies, pts receiving highly emetogenic chemotherapy (HEC) or moderately emetogenic chemotherapy (MEC) were randomized 1:1 to treatment with 180 mg oral rolapitant or placebo prior to chemotherapy, always with a 5-hydroxytryptamine type 3 RA and dexamethasone. Endpoints included complete response (CR; no emesis and no use of rescue medication), no emesis, no nausea (maximum visual analogue scale [VAS]

Results

CR rates, no emesis, and CP were significantly higher with rolapitant (P 

Conclusions

Rolapitant provides protection against CINV in elderly pts who were administered emetogenic chemotherapy.

Clinical trial identification

NCT01500226, NCT01499849, NCT01500213

Legal entity responsible for the study

TESARO, Inc.

Funding

TESARO, Inc.

Disclosure

M.S. Aapro: Consultant/Advisor (CA), Research Funding (RF), Speakers Bureau (SB): Helsinn, Hospira, Sandoz, PFM; CA/SB: Teva, Tesaro, Vifor Pharma; CA: Merck; RF: Novartis; SB: Amgen, Novartis, Roche, J&J; Honoraria & Expert Test: Amgen. S. Arora, D. Powers: Employment: Tesaro, Inc.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings